Scarica l'app Stockscreener
56.48
0.77%
0.43
Dopo l'orario di chiusura:
56.48
Vaxcyte Inc Borsa (PCVX) Ultime notizie
InvestingPro predicted Vaxcyte’s 49% decline two years ago By Investing.com - Investing.com
Current ratio of Vaxcyte, Inc. – HAN:5VA - TradingView
PCVX Maintains Buy Rating -- Price Target Lowered to $130 by B o - GuruFocus
Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says - marketscreener.com
BofA Securities Adjusts Vaxcyte Price Target to $130 From $133, Maintains Buy Rating - marketscreener.com
BofA cuts Vaxcyte stock price target on launch timeline shift - Investing.com
PCVX Reiterated by Needham -- Price Target Maintained at $110 - GuruFocus
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vaxcyte (PCVX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Vaxcyte stock gains 1.36 percent ahead of October data - AD HOC NEWS
(PCVX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com
Vaxcyte stock gains 1.36 percent as shares close at USD 58.92 - AD HOC NEWS
Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now? - Yahoo Finance
Vaxcyte, Inc. (PCVX) Stock Analysis: An Insight Into Its 87.51% Potential Upside - DirectorsTalk Interviews
Vaxcyte stock holds near USD 60.37 as estimates shift - AD HOC NEWS
Vaxcyte stock holds near recent highs as OPUS-1 Phase 3 data window narrows - AD HOC NEWS
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears - finance.yahoo.com
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 83% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes - Investing.com India
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - The Globe and Mail
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline - investing.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Australia
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):